1. Home
  2. TNXP vs WALD Comparison

TNXP vs WALD Comparison

Compare TNXP & WALD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$13.32

Market Cap

199.7M

Sector

Health Care

ML Signal

HOLD

Logo Waldencast plc

WALD

Waldencast plc

HOLD

Current Price

$1.38

Market Cap

187.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
WALD
Founded
2007
1988
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Package Goods/Cosmetics
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
199.7M
187.3M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
TNXP
WALD
Price
$13.32
$1.38
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$2.00
AVG Volume (30 Days)
486.9K
173.7K
Earning Date
05-11-2026
03-13-2026
Dividend Yield
N/A
N/A
EPS Growth
91.75
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
N/A
Revenue This Year
$558.11
$9.89
Revenue Next Year
$38.29
$4.31
P/E Ratio
N/A
N/A
Revenue Growth
29.85
N/A
52 Week Low
$9.40
$0.72
52 Week High
$29.19
$3.22

Technical Indicators

Market Signals
Indicator
TNXP
WALD
Relative Strength Index (RSI) 57.01 44.97
Support Level $11.98 $1.24
Resistance Level $13.36 $1.83
Average True Range (ATR) 0.71 0.08
MACD 0.04 0.01
Stochastic Oscillator 52.17 54.76

Price Performance

Historical Comparison
TNXP
WALD

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About WALD Waldencast plc

Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.

Share on Social Networks: